Phentolamine Mesylate (phentolamine mesylate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Phentolamine is an imidazoline alpha-adrenergic blocking agent.
Phentolamine is used mainly in the diagnosis of pheochromocytoma and to control or prevent paroxysmal hypertension immediately prior to or during pheochromocytomectomy.
Generic name: phentolamine mesylate
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Phentolamine Mesylate
Indications
The following indications are listed for Phentolamine Mesylate:
- Diagnostic Test For Pheochromocytoma
- Extravasation Injury
- Pheochromocytoma Adjunct Therapy
Also known as: Adjunct Medication Therapy For Pheochromocytoma, Diagnostic For Pheochromocytoma.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in rats and mice using oral phentolamine mesylate dosages 24-30 times the usual daily human dosage (based on a 60-kg individual) have shown slightly decreased fetal growth and slight fetal skeletal immaturity (manifested by an increased incidence of incomplete or unossified calcanei and phalangeal nuclei of the hind limb and of incompletely ossified sternebrae). In rats receiving oral dosages 60 times the usual human daily dosage (based on a 60-kg individual), a slightly decreased rate of implantation occurred. In rabbits receiving oral dosages 20 times the usual human daily dosage (based on a 60-kg individual), embryonic and fetal development were not affected. No teratogenic or embryotoxic effects were observed in reproduction studies in rats, mice, and rabbits. At least one human death has been reported following the phentolamine test during pregnancy. There are no adequate and well-controlled studies using phentolamine in pregnant women, and the drug should be used during pregnancy only when the potential benefits outweigh the possible risks to the fetus.
It is not known whether phentolamine mesylate is distributed into milk. Because of the potential for serious adverse reactions to phentolamine mesylate in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.